MDxHealth SA (NASDAQ:MDXH) Sees Significant Decline in Short Interest

MDxHealth SA (NASDAQ:MDXH) was the target of a large decline in short interest in the month of April. As of April 15th, there was short interest totaling 19,213 shares, a decline of 73.9% from the March 31st total of 73,632 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 262,452 shares, the days-to-cover ratio is currently 0.1 days.

MDxHealth Stock Down 1.9%

Shares of NASDAQ:MDXH traded down $0.04 during trading on Monday, reaching $2.04. 159,743 shares of the company traded hands, compared to its average volume of 157,198. The company’s 50 day moving average is $2.86 and its two-hundred day moving average is $3.44. The firm has a market capitalization of $100.98 million, a PE ratio of -3.04 and a beta of 1.73. MDxHealth has a 52 week low of $1.67 and a 52 week high of $5.33.

MDxHealth (NASDAQ:MDXH) last released its earnings results on Friday, February 27th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.04). The company had revenue of $29.55 million for the quarter, compared to the consensus estimate of $26.05 million. MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. As a group, research analysts anticipate that MDxHealth will post -0.41 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of MDxHealth in a research report on Friday, March 27th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, MDxHealth presently has a consensus rating of “Moderate Buy” and an average target price of $7.75.

Hedge Funds Weigh In On MDxHealth

A number of institutional investors have recently modified their holdings of MDXH. Calamos Advisors LLC acquired a new position in shares of MDxHealth during the 3rd quarter worth $305,000. GSA Capital Partners LLP acquired a new position in shares of MDxHealth during the 3rd quarter worth $48,000. Jefferies Financial Group Inc. acquired a new position in shares of MDxHealth during the 3rd quarter worth $53,000. Russell Investments Group Ltd. acquired a new position in shares of MDxHealth during the 3rd quarter worth $461,000. Finally, Kennedy Capital Management LLC acquired a new position in shares of MDxHealth during the 3rd quarter worth $1,826,000.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.